News » Visby Medical to Present at the J.P. Morgan 40th Annual Healthcare Conference

01/10/2022Press Release

Visby Medical to Present at the J.P. Morgan 40th Annual Healthcare Conference

Visby Medical™ announced that it will make its debut appearance at the 40th Annual J.P. Morgan Healthcare Conference.

Visby Medical to Present at the J.P. Morgan 40th Annual Healthcare Conference

SAN JOSE, Calif., Jan. 10, 2022Visby Medical™, a leading medical diagnostic company, today announced that it will make its debut appearance at the 40th Annual J.P. Morgan Healthcare Conference. Visby Founder and CEO Adam de la Zerda, PhD, will present virtually on Thursday, January 13, 2022, at 10:30 a.m. ET. During his presentation, de la Zerda will provide an overview of Visby’s latest developments in hand-held PCR technology, key strategic priorities for 2022 and the future of diagnostics in the age of telemedicine.

The live presentation will be streamed through the J.P. Morgan Healthcare Conference portal, and a recording of the presentation will be available after the event.

About Visby Medical™

Visby Medical is a diagnostics company that is transforming the order of diagnosis and treatment for infectious diseases. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. Visby Medical is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.

For more information, visit www.visbymedical.com. Follow Visby Medical on LinkedIn; Facebook, and Twitter.

Contact Visby’s Media team for any inquiries: press@visbymedical.com

 

Read more articles & insights

04/05/2024Viewpoint

The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

In light of the rising rates of sexually transmitted infections (STIs), urgent care clinics have found themselves at a crucial crossroads. PCR (Polymerase Chain Reaction) testing at the point of care emerges as a potential game-changer.

Read More
The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

03/14/2024Viewpoint

Understanding the Financial Impact of PCR Point of Care Testing for STIs

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
Understanding the Financial Impact of PCR Point of Care Testing for STIs

03/07/2024Viewpoint

5 Frequently Asked Questions on Implementing PCR into Urgent Care

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
5 Frequently Asked Questions on Implementing PCR into Urgent Care

02/21/2024Press Release

CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million to develop a portable polymerase chain reaction (PCR) test that can detect gonorrhea and assess its susceptibility to ciprofloxacin.

Read More
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test